Therapie der renalen Anämie - Optimierung durch langwirksames Erythropoese stimulierendes Arzneimittel

doi:10.1055/s-0028-1104654

Dialyse aktuell, Table of Contents

Dialyse aktuell 2008; 12(8): 510-511
DOI: 10.1055/s-0028-1104654

Forum der Industrie

Therapie der renalen Anämie - Optimierung durch langwirksames Erythropoese stimulierendes Arzneimittel

Abstract

Full Text

References

Literatur

01 McCellan W . Aronoff SL . Bolton WK . et al . The prevalence of anemia in patients with chronic kidney disease. Curr Med Res Opin. 2004; 20 1501-1510
02 Foley RN . Parfrey PS . Kent GM . et al . Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol. 2000; 11 912-916
03 Li S . Foley RN . Collins AJ . Anemia, hospitalization, and mortality in patients receiving peritoneal dialysis in the United States. Kidney Int. 2004; 65 1864-1869
04 Silverberg D . Outcomes of anaemia management in re nal insufficiency and cardiac disease. Nephrol Dial Transplant. 2003; 18 (Suppl. 2) ii7-12
05 KDOQI. Clinical practice guideline and clinical practice recommendations for anemia in chronic kidney disease: 2007 Update of Hemoglobin Target. www.kdoqi.org .
06 Revised European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant. 19 (Suppl. 2) ii1-ii47
07 Regidor DL . Kopple JD . Kovesdy CP . et al . Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. J Am Soc Nephrol. 2006; 17 1181-1191
08 Drüeke TB . Locatelli F . Clyne N . et al . Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006; 355 2071-2084
09 Müller HJ . Hahn K . Schneider HW . et al . Contributing factors to hb-cycling in a large cohort of esrd patients in germany. ASN 2006 in San Diego, Poster.
10 Fishbane S . Berns JS . Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kid Intern. 2005; 68 1337-1343
11 MacDougall IC . Walker R . Provenzano R . et al . C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered at extended intervals corrects anemia and maintains stable Hb levels in patients with CKD not on dialysis. ASN 2006 in San Diego, Poster.
12 Levin NW . Imbasciati E . Combe C . et al . Adequate Hb levels are maintained with IV C.E.R.A. (Continuous Erythropoietin Receptor Activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic Status. ASN 2006 in San Diego, Poster.
13 Sulowicz W . Locatelli F . Ryckelynck JP . et al . One-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007; 2 637-646
14 Westenbrink BD . Lipsic E . van der Meer P . et al . Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J. 2007; 28 2018-2027
15 Parsa CJ . Matsumoto A . Kim J . et al . A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest. 2003; 112 999-1007